Zynext Ventures Invests in Neuro42 Zynext Ventures Invests in neuro42, A Company Developing Portable MRI Systems for Neuroimaging and Interventions. Read More
Investment in Promaxo By Zynext Ventures Zynext Ventures, the VC arm of Zydus Lifesciences, Announces Investment in Promaxo: Pioneering Point-of-Care Medical Imaging and Interventions with Next Generation MRI Systems Read More
First drug approval for NASH Rezdiffra was approved under the accelerated approval pathway for the treatment of adults with NASH with moderate to advanced liver scarring, to be used along with diet and exercise. Read More
Cell and gene Therapy in rampage but expensive affair Cell and gene therapy (CGT) provides advanced medical treatments that revolutionise the approach and treatments where traditional pharma and small-molecule drugs are not viable. Read More
Zynext Ventures Invests in Neuro42 Zynext Ventures Invests in neuro42, A Company Developing Portable MRI Systems for Neuroimaging and Interventions. Read More
Investment in Promaxo By Zynext Ventures Zynext Ventures, the VC arm of Zydus Lifesciences, Announces Investment in Promaxo: Pioneering Point-of-Care Medical Imaging and Interventions with Next Generation MRI Systems Read More
First drug approval for NASH Rezdiffra was approved under the accelerated approval pathway for the treatment of adults with NASH with moderate to advanced liver scarring, to be used along with diet and exercise. Read More
Cell and gene Therapy in rampage but expensive affair Cell and gene therapy (CGT) provides advanced medical treatments that revolutionise the approach and treatments where traditional pharma and small-molecule drugs are not viable. Read More
